

INDEX

Note: Page numbers of article titles are in **boldface** type.

- A77003 (protease inhibitor), in HIV infection, 379
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Acridinium ester probe, in HIV detection, 317
- Adenoviruses, in gene therapy, for HIV infection, 380-381
- Aging, lead poisoning in, 438-439
- AIDS. See *Human immunodeficiency virus infection*.
- Air, lead release into, 425
- Alcohol ingestion, lead poisoning in, 438
- Alveolar macrophages, in HIV-specific cytotoxic T lymphocyte detection, 272-273
- Aminoglycosides, in HIV infection, 376
- Amplification, of DNA. See *Polymerase chain reaction*.
- Angry, in HIV infection, 229
- Antibodies, in gene therapy, for HIV infection, 381-382
in HIV infection, serologic assays for. See under *Serologic assays*.
- Anticoagulants, in samples, for reverse transcriptase-polymerase chain reaction, 338
- Antiretroviral drugs, **367-391**
affecting HIV replication, 368-380
at CD4 receptor binding step, 370-371
at cellular penetration step, 372
at host genome penetration step, 372
at transcription and translation stage, 373-379
at viral assembly stage, 379-382
at viral release stage, 379-382
efficacy of, monitoring of, 413-414
polymerase chain reaction in, 327-328, 344-346
HIV burden response to, 305-308
HIV resistance to, **393-422**
as pathogenic factor, 408-410
biochemical bases of, 404-407
efficacy monitoring in, 413-414
genetic factors in, 395-399
in combination therapy, 400-404
monitoring for, 410-413
mutations in, 400-404
replication dynamics and, 394-395
reverse transcriptase structure and, 404-407
- Antisense oligonucleotides, in HIV infection, 373-374
- Antisense RNA, in HIV infection, 374
- Apoptosis, of T lymphocytes, in HIV infection, 229-230
- Ateviridin, HIV resistance to, 397, 399
- 12-Azidododecanoic acid, in HIV infection, 377
- AZT. See *Zidovudine (AZT)*.
- Benzodiazepines, in HIV infection, 375-376
- Blood donors, HIV detection in, polymerase chain reaction in, 322
- Branch DNA signal amplification, in HIV detection, 337
- N-Butyl deoxyojirimicin, in HIV infection, 376-377
- Caffeic acid phenylethyl ester, in HIV infection, 372
- Calanolide, HIV resistance to, 399
- Camptothecin, in HIV infection, 372
- Castanospermine, in HIV infection, 376
- Cerebrospinal fluid, HIV in, 340
- Chromium, radioactive, in T-lymphocyte cytotoxicity assay, 277
- Cytokines, from cytotoxic T lymphocytes, in HIV infection pathogenesis, 287
- Cytotoxic T lymphocytes. See under *T lymphocytes*.

- ddC. See *Zalcitabine (ddC)*.
- ddl. See *Didanosine (dideoxyinosine, ddl)*.
- Delavirdine, HIV resistance to, 397, 399
- Dementia, AIDS, cytotoxic T lymphocytes in, 286-287
- Deoxyojirimicin, in HIV infection, 376
- Didanosine (dideoxyinosine, ddl), HIV resistance to, 396, 398
 as pathogenic factor, 408-409
 biochemical bases of, 406-407
 in combination therapy, 400
 laboratory monitoring of, 411
 in HIV infection, monitoring of, polymerase chain reaction in, 327
 virus burden response to, 305-306
- Dideoxyguanosine, HIV resistance to, biochemical bases of, 406
- Drugs, antiretroviral. See *Antiretroviral drugs*.
 lead interaction with, 438
- EBP-1, in HIV gene transcription, 244
- Elderly persons, lead poisoning in, 438-439
- Electrophoresis, in Western blot test, for HIV, 261
- ELISA (enzyme immunosorbent assay), for HIV antibodies, 258-260
- env* gene and gene product, 204-206, 243
 cytotoxic T lymphocytes recognizing, 283-284
- Enzyme immunosorbent assay, for HIV antibodies, 258-260
- Food, lead concentrations in, 427
- Foscarnet, HIV resistance to, 396
- gag* gene and gene product, 204-206, 211
 cytotoxic T lymphocytes recognizing, 278-279
- GEM 91, in HIV infection, 374
- Gene therapy, for HIV infection, 380-382
- Genotypic assays, for HIV drug resistance, 410-411
- Glycosylation, in HIV replication, inhibitors of, 376-377
- Gout, with lead poisoning, 424
- HEPT compounds, HIV resistance to, 397, 399
- HIV. See *Human immunodeficiency virus*.
- HIVEN 86A, in HIV gene transcription, 244
- Human immunodeficiency virus (type 1), ancillary proteins of, 212-216
 antibodies to, serologic assays for, 257-269
 assays for, 307-308
 in burden determination, 305
 clinical management and, 307-308
 clinical trial design and, 306-307
 in latent period, 240-242
 polymerase chain reaction in, 325-328
 in situ polymerase chain reaction in, 240-241, 351-365
 polymerase chain reaction in, 313-333
 reverse transcriptase-polymerase chain reaction in, 335-349
 serologic, 257-269
 burden of, 301-311
 drug resistance and, 394-395
 measurement of, 305
 clinical management and, 307-308
 clinical trial design and, 306-307
 in latent period, 240-242
 polymerase chain reaction in, 325-328
 phenotype significance in, 304-305
 vs. antiretroviral therapy response, 305-306
 vs. disease progression, 302-305
 cells infected by, 205, 207
 drug resistant. See *Antiretroviral drugs, HIV resistance to*.
 escape of, from cytotoxic T lymphocyte recognition, 287-290
 genes of, 205
 expression of, latency and, 242-246
 regulation of, 208-211
 virus burden and, 303
 genomic organization of, 204-205
 latency and, 242-246
 in body fluids, 340-341
 life cycle of, 203-204
 long terminal repeat of, 204, 208-210, 243-244
 molecular biology of, 203-220
 phenotype of, vs. disease progression, 304-305
 progression of, vs. virus burden, 302-305
 provirus of, 240-241, 246-248
 replication of, 211-212
 modes of, 302
 stages of, drugs affecting, 368-380
 reverse transcription of, 207-208
 strains of, vs. T-lymphocyte depletion kinetics, 232-234
 tissue dissemination of, polymerase chain reaction studies of, 324
 variation of, escape from T-lymphocyte recognition and, 288-289

- vs. type 2, polymerase chain reaction differentiation of, 324
- Human immunodeficiency virus (type 2),
 - genes of, 205-206
 - polymerase chain reaction identification of, 324
 - Western blot test for, 261-262
- Human immunodeficiency virus infection, asymptomatic. See also subhead: *latency in.*
 - polymerase chain reaction in, 321-326
 - serologic assays in, 263-264
 - diagnosis of, polymerase chain reaction in, 316-319
 - early events in, 205, 207-208
 - in pediatric patients, cytotoxic T lymphocyte function in, 285-286
 - polymerase chain reaction detection of, 323
 - latency in, 239-255. See also subhead: *asymptomatic.*
 - evidence for, 240-242
 - genome structure contribution to, 242-246
 - host factors in, 246-248
 - mathematical model of, 234
 - natural history of, neutralizing antibodies in, 264-266
 - pathogenesis of, cytotoxic T lymphocytes in, 286-287
 - drug resistance and, 408-410
 - polymerase chain reaction studies of, 324-327
 - seroconversion in, polymerase chain reaction detection before, 321-323
 - T lymphocytes in. See under *T lymphocytes.*
 - treatment of. See also *Antiretroviral drugs.*
 - gene therapy in, 380-382
 - polymerase chain reaction monitoring of, 327-328
 - virus burden response to, 305-306
 - vs. virus burden, 305-308
 - vaccines for, cytotoxic T lymphocytes induced by, 290-292
 - viremia in, vs. disease progression, 303-304
 - virus burden in. See *Human immunodeficiency virus (type 1), burden of.*
- Human leukocyte antigens, on cytotoxic T lymphocytes, HIV-specific, 274-275
- Hypericine, in HIV infection, 372
- Immunization, intracellular, in HIV infection, 380-382
- Immunoadhesins, CD4, antiretroviral activity of, 371
- Immunocapture reverse transcriptase test, for HIV, 263
- Immunofluorescence assay, for HIV antibodies, 258-259
- Immunomodulation, HIV in, 225-228
- In situ polymerase chain reaction, in HIV detection, 351-365
 - in latent period, 240-241
 - in replication studies, 356
 - percentage of cell infected, 356-357, 359-362
 - sensitivity of, 357-358
 - techniques for, 352-355
- Integrase inhibitors, in HIV infection, 372
- Interferons, in HIV infection, 376, 379-380
 - from cytotoxic T lymphocytes, 287
- Intracellular immunization, in HIV infection, 380-382
- Iron metabolism, lead poisoning and, 437
- Kaposi's sarcoma, interferon alpha for, 379-380
- L697,661 (antiretroviral drug), HIV resistance to, 394, 397, 399
 - as pathogenic factor, 408
- Lactation, lead poisoning in, 439
- Langerhans cells, HIV in, 341
- Latency, in HIV infection, 239-255, 263-264, 321-326
- Lead poisoning, 423-444
 - aging and, 438-439
 - alcohol ingestion and, 438
 - control of, 430-431, 433-434
 - definition of, blood levels in, 424-425
 - drug interactions in, 438
 - environmental contamination and, 425-427
 - from environmental exposure, 431-434
 - from increased tissue lead mobilization, 439
 - from occupational exposure, 428, 430-431
 - from paint, 424-425, 427
 - from recreational activities, 434
 - from substance abuse, 434-435
 - historical background of, 423-424
 - in developing nations, 427-428
 - in pediatric patients, 427, 431-434
 - iron interactions in, 437
 - lead absorption in, 435-436
 - pandemics of, 423-424
 - sources of, 428
 - toxicokinetics of, 436-437
 - trace mineral interactions in, 438

- Lead poisoning (*Continued*)
 vitamin D metabolism and, 438
- Leader binding protein-1, in HIV gene transcription, 245
- Lentiviruses, genomic organization of, 204–205
- Ligase chain reaction, in HIV detection, 262–263, 337
- Long terminal repeat, of HIV, 204, 208–210, 243–244
- Lymphocytes, T. See *T lymphocytes*.
- Lymphoid tissue, HIV in, 341
- Macrophages, alveolar, in HIV-specific cytotoxic T lymphocyte detection, 272–273
- Major histocompatibility complex, HIV infection effects on, 226–228
- 12-Methoxydodecanoic acid, in HIV infection, 377
- Minerals, dietary, lead interaction with, 438
- Mononuclear blood cells, peripheral. See *Peripheral blood mononuclear cells*.
- Multiplex method, for polymerase chain reaction, in HIV infection, 319
- Murine leukemia virus, genes of, 204, 206
- Myristoylation, in HIV replication, inhibitors of, 377–378
- nef* gene and gene product, 205–206, 211–214
 cytotoxic T lymphocytes recognizing, 284–285
- Negative regulatory element, of HIV gene, 244–245
- Neomycin B, in HIV infection, 376
- Neutralizing antibodies, in HIV infection, 264–266
- Nevirapine, HIV resistance to, 397, 399
 as pathogenic factor, 408, 410
 biochemical bases of, 404, 407
 in combination therapy, 400
- Nuclear factors, in HIV gene expression, 210, 244
- Occupational exposure, to lead, 428, 430–431
- Occupational Safety and Health Administration, lead exposure regulations of, 430–431
- Oligonucleotide(s), antisense, in HIV infection, 373–374
- Oligonucleotide solution hybridization technique, in HIV detection, 317
- Oncornaviruses, genomic organization of, 204–205
- p24 antigen, assays for, 262–264, 307–308
 in drug resistance, 412
- Paint, lead-containing, exposure to, 424–425, 427
- Pediatric patients, HIV infection in,
 cytotoxic T lymphocyte function in, 285–286
 polymerase chain reaction detection of, 323
 HIV testing in, 262
 lead exposure in, 427, 431–434
- Peripheral blood mononuclear cells, cytotoxic T lymphocytes in, HIV-specific, 272–274, 278–279, 283
 HIV burden in. See *Human immunodeficiency virus (type 1), burden of*.
- HIV DNA extraction from, 317
- HIV expression in, in asymptomatic disease, 324–325
 nonuniform drug resistant quasisppecies in, 394–395
 polymerase chain reaction detection of, 343. See also *In situ polymerase chain reaction*.
- vs. CD4 lymphocytes, 326
 HIV proviral sequences in, 240
- Phenotypic assays, for HIV drug resistance, 410, 412–413
- Phytohemagglutinin-simulated mononuclear cells, in HIV-specific cytotoxic T lymphocyte detection, 273
- Poisoning, lead. See *Lead poisoning*.
- pol* gene and gene product, 204–206, 211
- Polymerase chain reaction. See also *In situ polymerase chain reaction*; *Reverse transcriptase-polymerase chain reaction*.
 in HIV infection, 262–263, 313–333
 accuracy of, 318–319
 acridinium ester probe in, 317
 before seroconversion, 321–323
 carryover safeguards in, 316–317
 coamplification in, 321
 false results in, 317–318
 historical background of, 314–316
 hot-start method for, 315
 in diagnosis, 316–319
 in drug resistance detection, 410–411
 in infants of HIV-positive mothers, 323
 in pathogenesis studies, 324–327
 in research, 324
 in resolution of indeterminate serology, 323
 in therapy monitoring, 327–328
 multiplex method for, 319

- nested primers in, 315–316, 320
- Poisson statistics used in, 320
- practicality of, 318–319
- quantitation with, 319–321
- sample preparation for, 317
- sandwich system of, 317
- specificity enhancement of, 314–316
- Polymerase-specific cytotoxic T lymphocytes, in HIV infection, 279, 283
- Pregnancy, lead poisoning in, 439
- Protease inhibitors, in HIV infection, 378–379
- Pseudohypericin, in HIV infection, 372
- Pulmonary disease, in HIV infection, cytotoxic T lymphocytes in, 286

- Radioimmunoprecipitation assay, for HIV antibodies, 258–259
- Receptor interference, in HIV infection, 213
- Resistance, to antiretroviral drugs. See *Antiretroviral drugs, HIV resistance to.*
- Retroviruses. See also *Human immunodeficiency virus (type 1).*
 - genomic organization of, 204–205
 - viral latency and, 242–246
 - life cycle of, 203–204
- rev* gene and gene product, 205–206, 211, 243
 - inhibitors of, in HIV infection, 376
- Reverse transcriptase, cells expressing, cytotoxic T lymphocytes recognizing, 279, 283
 - structure of, drug resistance and, 404–407
- Reverse transcriptase-polymerase chain reaction, in HIV infection, 335–349
 - clinical applications of, 340–342
 - competitive template for, 339–340
 - external controls for, 339
 - in cells, 342–343
 - in plasma, 343–346
 - precision of, 337–338
 - priming in, 336
 - quantitation with, 339–340
 - sample handling for, 338–339
- rgp160, in HIV vaccine preparation, 291
- Ribozymes, in HIV infection, 374–375
- RNA, of HIV, antisense, 374
 - measurement of, 307–308
- Ro 5–3335 (benzodiazepine), in HIV infection, 375–376
- Ro 31–8959 (protease inhibitor), in HIV infection, 378–379

- Sandwich technique, in polymerase chain reaction, in HIV detection, 317
- Sarcoma, Kaposi's, interferon alpha for, 379–380
- Semen, HIV in, 341
- Serologic assays, in HIV infection, 257–269
 - for anti-HIV antibodies, confirmatory, 261–262
 - screening, 258–260
 - for neutralizing antibodies, 264–266
 - for p24 antigen, 262
 - for type 2 virus antibodies, 261–262
 - for viral DNA/RNA, 262–263
 - for virions, 262–263
 - prognostic value of, 263–264
- Soil, lead content of, 425–426
- Spumaviruses, genomic organization of, 204–205
- 3SR reaction, in HIV detection, 336
- Stool, HIV in, 340–341
- Superantigen effect, in HIV infection, T-lymphocyte depletion and, 228
- Sweat, HIV in, 341
- Syncytia formation, by T lymphocytes, in HIV infection, 232, 304–305, 408

- T lymphocytes, CD4, analogs of,
 - antiretroviral activity of, 370–371
- HeLa cell plaque reduction assay, in HIV drug resistance monitoring, 413
- HIV infection impact on, 205, 207–208, 221–238
 - anergy, 229
 - antiretroviral drugs affecting, 370–371
 - apoptosis, 229–230
 - direct cytopathy, 225
 - endocytosis, 213–214
 - immunomodulation, 225–228
 - in active disease, 231–232
 - in acute disease, 221–223
 - in quiescent disease, 223, 225–228
 - kinetics of depletion, 232–234
 - mechanisms of, 222
 - Nef protein and, 212–214
 - polymerase chain reaction studies of, 324–325, 342–343
 - precursor cell loss, 230–231
 - signaling defects, 228–230
 - superantigen effects, 228
 - syncytia formation, 232, 304–305, 408
 - time course of, 222
 - virus burden in, 302–305
 - recombinant soluble forms of,
 - antiretroviral activity of, 370–371
- CD8, HIV infection impact on, 223
- cytotoxic, in HIV infection, 271–299

- T lymphocytes (*Continued*)
 activity decline in, 289
 cloned, 273–274, 290
 cytotoxicity assay of, 277
 detection of, 272–277
 envelope-specific, 283–284
 epitopes recognized by, 277–285
 functions of, 285–290
 gag-specific, 278–279
 in pediatric patients, 285–286
 nef-specific, 284–285
 pathogenetic role of, 286–287
 polymerase-specific, 279, 283
 protective role of, 285–286
 target cell recognition in, 274–277
 vaccine-induced, 290–292
 viral escape from, 287–290
- TAR elements, of HIV gene, 208, 210
 in gene therapy, 381
- Target cells, for cytotoxic T-lymphocyte
 detection, 274–277
- tat* gene and gene product, 205–206, 211,
 243
 inhibitors of, in HIV infection, 375–376
- Tiacytidine (3TC), HIV resistance to, 396,
 398
 biochemical bases of, 406
- TIBO compounds, HIV resistance to, 397,
 399
- Topoisomerase inhibitors, in HIV infection,
 372
- Toxins, conjugated to CD4 cells,
 antiretroviral activity of, 371
- Transcription-based amplification system,
 in HIV detection, 336–337
- Transdominant mutant proteins,
 expression of, in gene therapy for HIV
 infection, 381
- TSAO compounds, HIV resistance to, 397,
 399
- Tumor necrosis factor, from cytotoxic T
 lymphocytes, in HIV infection
 pathogenesis, 287
- Untranslated binding protein, in HIV gene
 transcription, 245
- Upstream suppressor sequence, of HIV
 gene, 245
- Uracil *N*-glycosylase, in polymerase chain
 reaction, in HIV detection, 316
- Vaccines, for HIV infection, cytotoxic T
 lymphocytes induced by, 290–292
- vif* gene and gene product, 205–206, 211,
 214–215
- Viral culture, in HIV drug resistance
 monitoring, 412–413
- Viremia, in HIV infection, vs. disease
 progression, 303–304
- Vitamin D metabolism, lead poisoning and,
 438
- vpr* gene and gene product, 205–206, 211,
 215
- vpu* gene and gene product, 205–206, 211,
 215–216
- vpx* gene, 205–206
- Water, drinking, lead content of, 426–427
- Western blot test, in HIV infection, 261–262
 indeterminate, polymerase chain
 reaction resolution of, 323
- Zalcitabine (ddC), HIV resistance to, 396,
 398–399
 biochemical bases of, 406–407
 in combination therapy, 400
- Zidovudine (AZT), HIV resistance to, as
 pathogenic factor, 408–409
 biochemical bases of, 404, 406–407
 crossresistance of, 398
 genetic factors in, 395–396, 398
 in combination therapy, 400–404
 laboratory monitoring of, 410–413
 polymerase chain reaction studies of,
 324
 in HIV infection, efficacy of, monitoring
 of, 413–414
 interferon alpha with, 379–380
 monitoring of, polymerase chain reac-
 tion in, 327, 345–346
 virus burden response to, 305–308
 with *N*-butyl deoxyojirimicin, 377